Effects of chronic exposure of clonal β-cells to elevated glucose and free fatty acids on incretin receptor gene expression and secretory responses to GIP and GLP-1

Diabetes, Obesity and Metabolism

Volumn 16, Issue 4, 2014, Pages 357-365

  Pathak, V ^a   Vasu, S ^a   Flatt, P R ^a   Irwin, N ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Diabetes; Glucagon like peptide 1 (GLP 1); Glucose dependent insulinotropic polypeptide (GIP); Insulin release

Indexed keywords

FATTY ACID; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN; INSULIN; GASTRIC INHIBITORY POLYPEPTIDE RECEPTOR; GLUCOSE BLOOD LEVEL; HORMONE RECEPTOR;

ANIMAL CELL; ARTICLE; CELL COUNT; CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; GENE EXPRESSION; HORMONE ACTION; HORMONE RELEASE; INSULIN RELEASE; LONG TERM EXPOSURE; MALE; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; RECEPTOR GENE; BLOOD; GLUCOSE BLOOD LEVEL; HUMAN; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; SECRETION (PROCESS); WESTERN BLOTTING;

BLOOD GLUCOSE; BLOTTING, WESTERN; CELLS, CULTURED; DIABETES MELLITUS, TYPE 2; FATTY ACIDS, NONESTERIFIED; GASTRIC INHIBITORY POLYPEPTIDE; GENE EXPRESSION; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HUMANS; INCRETINS; INSULIN; INSULIN-SECRETING CELLS; RECEPTORS, GASTROINTESTINAL HORMONE;

EID: 84895128762     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12227     Document Type: Article

References (39)

1. Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 2013; 17: 819-837.
2. Scrocchi LA, Brown TJ, MaClusky N et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med 1996; 2: 1254-1258.
3. Tseng CC, Boylan MO, Jarboe LA, Usdin TB, Wolfe MM. Chronic desensitization of the glucose-dependent insulinotropic polypeptide receptor in diabetic rats. Am J Physiol 1996; 270: E661-E666.
4. Schirra J, Sturm K, Leicht P, Arnold R, Göke B, Katschinski M. Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans. J Clin Invest 1998; 101: 1421-1430.
5. Miyawaki K, Yamada Y, Yano H et al. Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci U S A 1999; 96: 14843-14847.
6. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993; 91: 301-307.
7. Gault VA, O'Harte FP, Harriott P, Mooney MH, Green BD, Flatt PR. Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin. Diabetologia 2003; 46: 222-230.
8. Irwin N, Flatt PR. GIP. In: Kastin AJ, ed. Handbook of Biologically Active Peptides. San Diego: Elsevier, 2013; 1227-1236.
9. Irwin N, Gault V, Flatt PR. Therapeutic potential of the original incretin hormone glucose-dependent insulinotropic polypeptide: diabetes, obesity, osteoporosis and Alzheimer's disease? Expert Opin Invest Drug 2010; 19: 1039-1048.
10. Xu G, Kaneto H, Laybutt DR et al. Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes. Diabetes 2007; 56: 1551-1558.
11. Lynn FC, Thompson SA, Pospisilik JA et al. A novel pathway for regulation of glucose-dependent insulinotropic polypeptide (GIP) receptor expression in beta cells. FASEB J 2003; 17: 91-93.
12. McIntosh CH, Widenmaier S, Kim SJ. Glucose-dependent insulinotropic polypeptide (Gastric Inhibitory Polypeptide; GIP). Vitam Horm 2009; 80: 409-471.
13. Younan SM, Rashed LA. Impairment of the insulinotropic effect of gastric inhibitory polypeptide (GIP) in obese and diabetic rats is related to the down-regulation of its pancreatic receptors. Gen Physiol Biophys 2007; 26: 181-193.
14. Piteau S, Olver A, Kim SJ et al. Reversal of islet GIP receptor down-regulation and resistance to GIP by reducing hyperglycemia in the Zucker rat. Biochem Biophys Res Commun 2007; 362: 1007-1012.
15. McClenaghan NH, Flatt PR, Ball AJ. Actions of glucagon-like peptide-1 on KATP channel-dependent and -independent effects of glucose, sulphonylureas and nateglinide. J Endocrinol 2006; 190: 889-896.
16. Ball AJ, Flatt PR, McClenaghan NH. Acute and long-term effects of nateglinide on insulin secretory pathways. Br J Pharmacol 2004; 142: 367-373.
17. Irwin N, McKinney JM, Bailey CJ, Flatt PR, McClenaghan NH. Effects of metformin on BRIN-BD11 beta-cell insulin secretory desensitization induced by prolonged exposure to sulphonylureas. Diabetes Obes Metab 2010; 12: 1066-1071.
18. McClenaghan NH, Barnett CR, O'Harte FP, Flatt PR. Mechanisms of amino acid-induced insulin secretion from the glucose-responsive BRIN-BD11 pancreatic B-cell line. J Endocrinol 1996; 151: 349-357.
19. McKiney JM, Irwin N, Flatt PR, Bailey CJ, McClenaghan NH. Acute and long-term effects of metformin on the function and insulin secretory responsiveness of clonal β-cells. Biol Chem 2010; 391: 1451-1459.
20. Flatt PR, Bailey CJ. Abnormal plasma glucose and insulin responses in heterozygous (ob/+) mice. Diabtelogia 1981; 20: 573-577.
21. Lacy PE, Kostianovsky M. Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes 1967; 16: 35-39.
22. Vasu S, McClenaghan NH, McCluskey JT, Flatt PR. Effects of lipotoxicity on novel insulin secreting human pancreatic β-cell line, 1.1B4. Biol Chem 2013; 394: 909-918.
23. McCluskey JT, Hamid M, Guo-Parke H, McClenaghan NH, Gomis R, Flatt PR. Development and functional characterization of insulin-releasing human pancreatic beta cell lines produced by electrofusion. J Biol Chem 2011; 286: 21982-21992.
24. Flatt PR, Bailey CJ, Green BD. Recent advances in antidiabetic drug therapies targeting the enteroinsular axis. Curr Drug Metab 2009; 10: 125-137.
25. Meglasson M, Matschinsky F. Pancreatic islet glucose metabolism and regulation of insulin secretion. Diabetes Metab Rev 1986; 2: 163-214.
26. Lynn FC, Pamir N, Ng EH, McIntosh CH, Kieffer TJ, Pederson RA. Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. Diabetes 2001; 50: 1004-1011.
27. Hamid M, McCluskey JT, McClenaghan NH, Flatt PR. Comparison of the secretory properties of four insulin-secreting cell lines. Endocr Res 2002; 28: 35-47.
28. Tajima K, Shirakawa J, Togashi Y et al. AMPK is involved in the regulation of incretin receptors expression in pancreatic islets under a low glucose concentration. PLoS One 2013; 8: 1-12.
29. Kanda Y, Shimoda M, Hamamoto S et al. Molecular mechanism by which pioglitazone preserves pancreatic beta-cells in obese diabetic mice: evidence for acute and chronic actions as a PPAR gamma agonist. Am J Physiol Endocrinol Metab 2010; 298: E278-E286.
30. Gupta D, Peshavaria M, Monga N, Jetton TL, Leahy JL. Physiologic and pharmacologic modulation of glucose-dependent insulinotropic polypeptide (GIP) receptor expression in beta-cells by peroxisome proliferator-activated receptor (PPAR)-gamma signalling: possible mechanism for the GIP resistance in type 2 diabetes. Diabetes 2010; 59: 1445-1450.
31. Kim SJ, Nian C, McIntosh CH. Adipocyte expression of the glucose-dependent insulinotropic polypeptide receptor involves gene regulation by PPARγ and histone acetylation. J Lipid Res 2011; 52: 759-770.
32. Irwin N, McKinney JM, Bailey CJ, McClenaghan NH, Flatt PR. Acute and long-term effects of peroxisome proliferator-activated receptor-γ activation on the function and insulin secretory responsiveness of clonal beta-cells. Horm Metab Res 2011; 43: 244-249.
33. Gupta D, Leahy AA, Monga N, Peshavaria M, Jetton TL, Leahy JL. Peroxisome Proliferator-activated Receptor γ (PPARγ) and Its Target Genes Are Downstream Effectors of FoxO1 Protein in Islet β-Cells: mechanism of β-cell compensation and failure. J Biol Chem 2013; 288: 25440-25449.
34. Sonestedt E, Lyssenko V, Ericson U et al. Genetic variation in the glucose-dependent insulinotropic polypeptide receptor modifies the association between carbohydrate and fat intake and risk of type 2 diabetes in the Malmo Diet and Cancer cohort. J Clin Endocrinol Metab 2012; 97: E810-E818.
35. Saxena R, Hivert MF, Langenberg C et al. Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet 2010; 42: 142-148.
36. Shu L, Matveyenko AV, Kerr-Conte J, Cho JH, McIntosh CH, Maedler K. Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function. Hum Mol Genet 2009; 18: 2388-2399.
37. Yabe D, Seino Y. Two incretin hormones GLP-1 and GIP: comparison of their actions in insulin secretion and β cell preservation. Prog Biophys Mol Biol 2011; 107: 248-256.
38. Whitaker GM, Lynn FC, McIntosh CH, Accili EA. Regulation of GIP and GLP1 receptor cell surface expression by N-glycosylation and receptor heteromerization. PLoS One 2012; 7: 1-15.
39. Miki T, Minami K, Shinozaki H et al. Distinct effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 on insulin secretion and gut motility. Diabetes 2005; 54: 1056-1063.